Article Contents ::
- 1 The Brand Name BITAFIT Has Generic Salt :: Metoprolol
- 2 BITAFIT Is From Company Unisearch Priced :: Rs. 42
- 3 BITAFIT have Metoprolol is comes under Sub class Anti Anginals of Main Class Cardiovascular System
- 4 Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Anginals
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name BITAFIT Has Generic Salt :: Metoprolol
BITAFIT Is From Company Unisearch Priced :: Rs. 42
BITAFIT have Metoprolol is comes under Sub class Anti Anginals of Main Class Cardiovascular System
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Anginals
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Brand Name||Company / Manufacturers||Strength||Unit||Price / 10|
|Company Brand Name||Salt Combination||Main Medical Class||Sub Medical Class|
|From Unisearch :: BITAFIT||Metoprolol||Cardiovascular System||Anti Anginals|
Indications for Drugs ::
Heart failure, Migraine, Acute MI, Diabetic nephropathy, Hypertension, Cardiac arrhythmias, Angina pectoris
Drug Dose ::
Hypertension: initially 100mg daily, maintenance 100-200mg daily in 1-2 divided doses Angina Pectoris: 50-100mg 2-3 times daily. Myocardial Infarction: After early intravenous treatment for 48 hours, patients should receive a maintenance dose of 100mg twice daily. Arrhythmias: usually 50mg 2-3 times daily; up to 300mg daily in divided doses if necessary. Hyperthyroidism: (adjunct), 50mg 4 times daily Migraine Prophylaxis: 100-200mg daily in divided doses.
Hypertension and Angina: Metoprolol is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure. Myocardial Infarction: Metoprolol is contraindicated in patients with a heart rate<45 beats/min; second and third-degree heart block; significant first-degree heart block; systolic blood pressure <100 mmHg; or moderate-to-severe cardiac failure. Drug Precautions ::
Gereral: Metoprolol should be used with caution in patients with impaired hepatic function. Information for Patients: Patients should be advised to take Metoprolol regularly and continuously, as directed, with or immediately following meals. If a dose missed, the patient should take only the next scheduled dose (without doubling it). Patient should not discontinue Metoprolol without consulting the physician. Patients should be advised to avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient’s response to therapy with Metoprolol has been determined. contact the physician if any difficulty in breathing occurs. inform the physician or dentist before any type of surgery that he or she is taking Metoprolol.
Drug Side Effects ::
Bradycardia, Heart failure, hypotension, Conduction disorder, Bronchospasm, Peripheral vasoconstriction, Gastrointestinal disturbances, Fatigue, Sleep disturbance, Rare reports of rashes and dry eyes, Sexual dysfunction, and Exacerbation of psoriasis.
Pregnancy category ::
Drug Mode of Action ::
Metoprolol selectively inhibits ?1-adrenergic receptors but has little or no effect on ?2-receptors except in high doses. It does not exhibit membrane stabilising or intrinsic sympathomimetic activity.
Drug Interactions ::
Additive effect w/ catecholamine-depleting drugs (e.g. reserpine) and MAOIs. May antagonise ?1-adrenergic stimulating effects of sympathomimetics. Additive negative effects on SA or AV nodal conduction w/ cardiac glycosides, nondihydropyridine Ca channel blockers. Paradoxical response to epinephrine may occur. Increased plasma concentrations w/ CYP2D6 inhibitors (e.g. bupropion, cimetidine). Increased risk of hypotension and heart failure w/ myocardial depressant general anaesth (e.g. diethyl ether). Risk of pulmonary HTN w/ vasodilators (e.g. hydralazine) in uraemic patients. Reduced plasma levels w/ rifampicin. May increase negative inotropic and negative dromotropic effect of antiarrhythmic drugs (e.g. quinidine, amiodarone). May reduce antihypertensive efficacy w/ indometacin. May increase effects of hypoglycaemics.